AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
+7.09%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$166M
AUM Growth
+$166M
(+11%)
Cap. Flow
+$18.9M
Cap. Flow
% of AUM
11.41%
Top 10 Holdings %
Top 10 Hldgs %
22.19%
Holding
254
New
38
Increased
43
Reduced
118
Closed
26
Top Buys
| 1 |
United Therapeutics
UTHR
|
$3.68M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$2.78M |
| 3 |
Pfizer
PFE
|
$2.64M |
| 4 |
Axsome Therapeutics
AXSM
|
$2.59M |
| 5 |
Corcept Therapeutics
CORT
|
$2.14M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$3.78M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
$3.13M |
| 3 |
ABVX
Abivax
ABVX
|
$2.86M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
$2.8M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$2.22M |
Sector Composition
| 1 | Healthcare | 61.45% |
| 2 | Real Estate | 11.2% |
| 3 | Financials | 4.6% |
| 4 | Industrials | 3.92% |
| 5 | Technology | 2.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Royalty Pharma
RPRX
$15.6B
| $1.82M | 1.1% |
60,000
+20,000
| +50% | +$607K |
|
|
CERE
27
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.8M | 1.08% |
42,500
+17,500
| +70% | +$740K |
|
28
Medtronic
MDT
$120B
| $1.79M | 1.08% |
20,500
| – | – |
|
29
Karyopharm Therapeutics
KPTI
$59.1M
| $1.7M | 1.02% |
1,125,000
| – | – |
|
30
Celldex Therapeutics
CLDX
$1.5B
| $1.62M | 0.97% |
+38,500
| New | +$1.62M |
|
31
Invesco S&P 500 Pure Value ETF
RPV
$1.35B
| $1.58M | 0.95% |
+17,834
| New | +$1.58M |
|
32
Stereotaxis
STXS
$245M
| $1.57M | 0.94% |
600,000
| – | – |
|
33
iShares Russell 1000 Value ETF
IWD
$62.9B
| $1.55M | 0.94% |
+8,671
| New | +$1.55M |
|
34
KalVista Pharmaceuticals
KALV
$708M
| $1.54M | 0.93% |
130,000
-7,000
| -5% | -$83K |
|
35
Dynavax Technologies
DVAX
$1.18B
| $1.52M | 0.92% |
122,500
+22,500
| +23% | +$279K |
|
36
GSK
GSK
$78B
| $1.5M | 0.91% |
35,000
| – | – |
|
|
BCYC
37
Bicycle Therapeutics
BCYC
$507M
| $1.49M | 0.9% |
+60,000
| New | +$1.49M |
|
38
ArriVent BioPharma
AVBP
$802M
| $1.48M | 0.89% |
+83,000
| New | +$1.48M |
|
39
Embecta
EMBC
$847M
| $1.48M | 0.89% |
111,500
-88,500
| -44% | -$1.17M |
|
40
Viking Therapeutics
VKTX
$2.99B
| $1.48M | 0.89% |
+18,000
| New | +$1.48M |
|
|
NYMT
41
New York Mortgage Trust
NYMT
$636M
| $1.45M | 0.87% |
200,963
| – | – |
|
42
Synopsys
SNPS
$109B
| $1.43M | 0.86% |
2,500
+400
| +19% | +$229K |
|
43
Tourmaline Bio
TRML
$605M
| $1.4M | 0.84% |
+61,100
| New | +$1.4M |
|
|
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.38M | 0.83% |
20,000
| – | – |
|
45
VYNE Therapeutics
VYNE
$8.31M
| $1.37M | 0.82% |
445,000
-223,151
| -33% | -$685K |
|
46
BioMarin Pharmaceuticals
BMRN
$11.2B
| $1.35M | 0.82% |
15,500
+1,500
| +11% | +$131K |
|
47
Equity Lifestyle Properties
ELS
$11.5B
| $1.33M | 0.8% |
20,611
| – | – |
|
48
Enact Holdings
ACT
$5.52B
| $1.32M | 0.8% |
42,367
| – | – |
|
|
MITT
49
AG Mortgage Investment Trust
MITT
$238M
| $1.28M | 0.77% |
208,879
| – | – |
|
50
Procept Biorobotics
PRCT
$2.19B
| $1.24M | 0.75% |
+25,000
| New | +$1.24M |
|